Cardinal Health, Inc. (CLH.F)
| Previous Close | 95.72 |
| Open | 91.54 |
| Bid | 91.58 x 20000 |
| Ask | 92.38 x 20000 |
| Day's Range | 91.54 - 91.54 |
| 52 Week Range | 75.52 - 106.30 |
| Volume | |
| Avg. Volume | 35 |
| Market Cap | 22.296B |
| Beta (5Y Monthly) | 0.70 |
| PE Ratio (TTM) | 42.98 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.88 (1.99%) |
| Ex-Dividend Date | Mar 28, 2024 |
| 1y Target Est | N/A |
- PR Newswire
Cardinal Health Reports Third Quarter Fiscal Year 2024 Results and Raises Fiscal Year 2024 Non-GAAP EPS Guidance
Cardinal Health (NYSE: CAH) today reported third quarter fiscal year 2024 revenues of $54.9 billion, an increase of 9% from the third quarter of fiscal year 2023. Third quarter GAAP operating earnings were $367 million and GAAP diluted earnings per share (EPS) were $1.05, which included a non-cash, pre-tax goodwill impairment of $90 million related to the Global Medical Products and Distribution (GMPD) segment as a result of the reallocation of goodwill related to the reporting structure update.
- PR Newswire
Cardinal Health Reaffirms Fiscal 2024 non-GAAP EPS Guidance and Long-term Targets Amidst Nonrenewal of OptumRx Customer Contracts
Cardinal Health (NYSE: CAH) announced today that its pharmaceutical distribution contracts with OptumRx, which expire at the end of June 2024, will not be renewed. The company reaffirmed its fiscal 2024 non-GAAP diluted EPS guidance of $7.20 to $7.35. Despite the nonrenewal of the OptumRx contracts, the company also reiterated both its Pharmaceutical and Specialty Solutions long-term segment profit CAGR target of 4% to 6% and its consolidated non-GAAP EPS CAGR target of 12% to 14% for fiscal yea
- PR Newswire
Cardinal Health announces location of pharmaceutical distribution center for over-the-counter products
Today, Cardinal Health (NYSE: CAH) announced that construction has begun for a new 350,000 square-foot logistics center in Columbus, Ohio, that will serve as a centralized replenishment center for the distribution of over-the-counter consumer health products in support of its core pharmaceutical business.
